$2.80
Today
as of Sep 4, 16:52 ET
Last 30 days
Recent Press Releases & News
Ovid Therapeutics to Participate in Upcoming Investor Conferences
What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?
Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates
Overview
52-week range
$1.12
$3.10
85% of range
Avg surprise (last 3)
+20.8%
Avg reaction (last 2)
-1.2%
50% positive
Latest IV / EM
194%
EM ±30.4% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.12 | $-0.12 | 0.0% | +14.3% | +2.9% | earnings |
| Wed Aug 13, 2025 | Jun/2025 | $-0.06 | $-0.16 | +62.5% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.14 | $-0.14 | 0.0% | — | -5.3% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.20 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.12 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.17 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.16 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.18 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.19 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $733,000 | $0 | — | $132,000 | $6M | $130,000 | — | $173,000 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-16M | $-18M | — | $-13M | $-5M | $-13M | — | $-13M |
| Net income | $-15M | $-17M | — | $-12M | $-5M | $-10M | — | $-14M |
| EPS (diluted) | — | — | — | — | — | — | — | $-0.20 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11M | $94M | $13M | $21M | $28M | $21M | $26M | $15M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $124M | $160M | $74M | $29M | $42M | $46M | $56M | $66M |
| Total assets | $232M | $226M | $151M | $64M | $77M | $82M | $92M | $103M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $22M | $27M | $20M | $19M | $22M | $22M | $24M | $26M |
| Total equity | $210M | $198M | $131M | $45M | $56M | $59M | $68M | $76M |